Novel Technique Could Lead to Potential Therapy for Huntington’s Disease

News

Published: June 30, 2023

| Original story from the University of Gothenburg

A 3D model of a human brain and a neuron cell.

Credit: Robina Weermeijer / Unsplash.

Want a FREE PDF version of this news story?

Complete the form below and we will email you a PDF version of "Novel Technique Could Lead to Potential Therapy for Huntington’s Disease"

First Name*

Last Name*

Email Address*

Country*

Company Type*

Job Function*

Would you like to receive further email communication from Technology Networks?

Listen with

Speechify

0:00

Thank you. Listen to this article using the player above. ✖

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: 2 minutes

Summary

A new study by Gothenburg University and the Max Planck Institute describes an engineered approach to manipulate protein aggregates associated with neurodegenerative diseases. The method successfully removed aggregates in yeast and human cells, offering potential therapeutic applications and insights into these diseases.

Key Takeaways

Protein aggregates are associated with neurodegenerative diseases like Alzheimer's, Parkinson's, and Huntington's.

Researchers developed an engineered approach to manipulate protein aggregates in yeast and human cells.

The synthetic export system successfully removed protein aggregates, offering potential for future therapeutic applications and better understanding of neurodegenerative diseases.

Protein aggregates accumulate during aging and are linked to neurodegenerative diseases like Alzheimer’s, Parkinson’s or Huntington’s disease. A new study by the Nyström lab at Gothenburg University, in collaboration with the Max Planck Institute for Biology of Ageing in Germany, describes a novel, engineered approach that makes protein aggregates amenable to spatial manipulations in both budding yeast and human cells.

Want more breaking news?

Subscribe to Technology Networks’ daily newsletter, delivering breaking science news straight to your inbox every day.

Subscribe for FREE

Many neurodegenerative diseases like Alzheimer’s, Parkinson’s or Huntington’s disease are associated with the aggregation of misfolded proteins but whether or not these aggregates contribute to these diseases is not clear.

The research group of Professor Thomas Nyström from Gothenburg University was able to export such protein aggregates from cells in an engineered manner, which was published in the journal Nature Communications. The system was first developed in the widely-used model organism, budding yeast, but was extended also for use in human cells.

Free of protein aggregates

The authors achieved this synthetic cellular export system by fusing an aggregate-binding protein to a daughter-cell-targeting factor such that when the daughter cell is pinched off, the mother cell is free of protein aggregates. This approach was effective in dealing with endogenous, age-associated protein aggregates, as well as with mutant Huntingtin aggregates associated with the Huntington’s disease.

Using this daughter targeting system, they showed that the export of mutant Huntingtin protected yeast mother cells from cell death suggesting that large Huntingtin aggregates may be highly toxic and contribute to the disease, a trait that has been widely debated.

Potential future therapy

“To our knowledge this is the first demonstration that protein aggregates can be exported from cells in a controlled, engineered manner. Other kinds of cellular damage might be also exported from cells with adapted versions of our targeting system”, says Dr. Arthur Fischbach, postdoc and the lead author of the study.

“Although we currently lack supporting data, there is a possibility that the ATS concept could be employed in the future as a potential novel therapeutic approach for neurodegenerative diseases or at least for gaining a better understanding of them. Given the urgency, there is a strong demand for innovative therapies in this area”, he concludes.

Reference: Fischbach A, Johns A, Schneider KL, Hao X, Tessarz P, Nyström T. Artificial Hsp104-mediated systems for re-localizing protein aggregates. Nat Commun. 2023;14(1):2663. doi: 10.1038/s41467-023-37706-3

This article has been republished from the following materials. Article summaries may be generated using fact-checked AI models. Note: material may have been edited for length and content. For further information, please contact the cited source.

Biopharma